About MorphImmune
MorphImmune is a private company based in West Lafayette, Indiana, incorporated in 2020 in Delaware. It has reported $32,135,765 raised in two offerings on Form D since February 2022. Its chief executive is Clay Siegall, Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 5, 2023 | May 17, 2023 | $15,000,000fully sold | 11 | $1.3M | EquityRule 506(b) | Form D ↗ |
| Feb 4, 2022 | Feb 17, 2022 | $17,135,765of $19.0M target | 18 | $951K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $32,135,765 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on MorphImmune's Form D filed May 17, 2023.
SD
Sunil Singhal, M.D.
Director
PD
Philip Low, Ph.D.
Director
IB
Isaac Barchas
Director
CD
Clay Siegall, Ph.D.
President and Chief Executive Officer, director
RM
Ronald Martell
Director
FD